Short- and long-term effects of T-cell modulating agents in experimental autoimmunity

Toxicology

Volumn 196, Issue 3, 2004, Pages 197-209

  Mellergård, Johan ^a   Havarinasab, Said ^a   Hultman, Per ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Autoimmunity; Cyclosporin; Mercuric chloride; Mice; T cells; Tacrolimus

Indexed keywords

CD4 ANTIGEN; CYCLOSPORIN A; DRINKING WATER; FIBRILLARIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; INTERLEUKIN 4; MERCURY; MONOCLONAL ANTIBODY; OKT 4; SODIUM CHLORIDE; TACROLIMUS;

ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CHROMATIN; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; EXPERIMENTAL MODEL; FEMALE; GENETIC SUSCEPTIBILITY; HYPERIMMUNOGLOBULINEMIA; IMMUNE COMPLEX DEPOSITION; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RODENT; T LYMPHOCYTE;

BUBALUS DEPRESSICORNIS; RODENTIA;

EID: 1242292924     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2003.10.004     Document Type: Article

References (45)

1. Abed N.S., Chace J.H., Fleming A.L., Cowdery J.S. Interferon-gamma regulation of B lymphocyte differentiation: activation of B cells is a prerequisite for IFN-gamma-mediated inhibition of B cell differentiation. Cell. Immunol. 153:1994;356-366.
2. Aten J., Bosman C., de Heer E., Hoedemaeker P., Weening J.S. Cycloporin A induces long-term unresponsiveness in mercuric chloride-induced autoimmune glomerulonephritis. Clin. Exp. Immunol. 73:1988;307-311.
3. Bigazzi, P.E., 1998. Animal models of autoimmunity: spontaneous and induced. In: Rose, N.R., Mackay, I.R. (Eds.), The Autoimmune Diseases, Academic Press, San Diego, New York, pp. 211-245.
4. Bigazzi P.E. Metals and kidney autoimmunity. Envirn. Health Perspect. 107:1999;753-765.
5. Borchers A., Keen C., Shoenfeld Y., Gershwin M. How to outfox mother nature-autoimmunity: moving from shadows to sunshine. Isr. Med. Assoc. J. 2:2000;S15-S22.
6. Bundick R., Craggs R., Holness E. The effect of cyclosporin A, FK 506, and rapamycin on the murine chronic graft-versus-host response - an in vivo model of Th2 like activity. Clin. Exp. Immunol. 99:1995;467-472.
7. Burkhardt H., Kalden J. Xenobiotic immunosuppressive agents: therapeutic effects in animal models of autoimmune diseases. Rheumatol. Int. 17:1997;85-90.
8. Cautain B., Damoiseaux J., Bernard I., Xystrakis E., Fournie E., van Breda Vriesman P., Druet P., Saoudi A. The CD8 T-cell compartment plays a dominant role in the deficiency of Brown-Norway rats to mount a proper type 1 immune response. J. Immunol. 168:2002;162-170.
9. Cowdery J. Chronic in vivo depletion of CD4 T-cells increases both IgM levels and the expressed frequency of anti-ssDNA precursors in both NZB and DBA/2 mice. Clin. Immunol. Immunopathol. 56:1990;360-372.
10. + T-cells increases B-cell sensitivity to polyclonal activation: the role of interferon-gamma. Clin. Immunol. Immunopathol. 62:1992;72-77.
11. Dumont F.J. FK506, an immunosuppressant targeting calcineurin function. Curr. Med. Chem. 7:2000;731-748.
12. + T-cells. Clin. Immunol. Immunopathol. 69:1993;285-291.
13. Fournié G.J., Saoudi A., Druet P., Pelletier L. Th2-type immunopathological manifestations induced by mercury chloride or gold salts in the rat: signal transduction pathways, cellular mechanisms, and genetic control. Autoimm. Rev. 1:2002;205-212.
14. Furukawa F., Imamura S., Takigawa M. FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL-lpr/lpr mice. Arch Derm Res. 287:1995;558-563.
15. Gorantla V., Barker J., Jones J., Prabhune K., Maldonado C., Granger D. Immunosuppressive agents in transplantation: mechanisms of action and current anti-rejection strategies. Microsurgery. 20:2000;420-429.
16. Goter Robinson C., White H., Rose N. Murine strain differences in response to mercuric chloride: antinucleolar antibodies production does not correlate with renal immune complex deposition. Clin. Immunol. Immunopathol. 83:1997;127-138.
17. Gunn H. Succesful treatment of autoimmunity in (NZB × NZW) F1 mice with cyclosporin and (Nva2)-cyclosporin: 1. Reduction of autoantibodies. Clin. Exp. Immunol. 64:1983;225-233.
18. Häggqvist B., Hultman P. Effects of deviating the Th2-response in murine mercury-induced autoimmunity towards a Th1-response. Clin. Exp. Immunol. 134:2003;202-209.
19. Hall B. Mechanisms of induction of tolerance to organ allografts. Crit. Rev. Immunol. 20:2000;267-324.
20. Hart T., Blackburn N., Brigham-Burke M., Dede K., Al-Mahdi N., Zia-Amirhosseini P., Cook R. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanised anti-interleukin-4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol. 130:2002;93-99.
21. Hultman P., Bell L.J., Eneström S., Pollard K.M. Murine susceptibility to mercury. I. Autoantibody profiles and systemic immune deposits in inbred, congenic, and intra-H-2-recombinant strains. Clin. Immunol. Immunopathol. 65:1992;98-109.
22. Hultman P., Eneström S. The induction of immune-complex deposits in mice by peroral and parenteral administration of mercuric chloride. Clin. Exp. Immunol. 67:1987;283-292.
23. Hultman P., Eneström S. Mercury induced antinuclear antibodies in mice: characterization and correlation with renal immune complex deposits. Clin. Exp. Immunol. 71:1988;269-274.
24. Hultman P., Eneström S. Murine mercury-induced immune-complex disease: effect of cyclophosphamide treatment and importance of T-cells. Br. J. Exp. Pathol. 70:1989;227-236.
25. Hultman P., Johansson U., Dagnaes-Hansen F. Murine mercury-induced autoimmunity: the importance of T-cells. J. Autoimm. 8:1995;809-824.
26. Hultman P., Turley S.J., Eneström S., Lindh U., Pollard K.M. Murine genotype influences the specificity, magnitude and persistence of murine mercury-induced autoimmunity. J. Autoimm. 9:1996;139-149.
27. Izui S., Kobayakawa T., Zryd M.J., Louis J., Lambert P.H. Mechanism for induction of anti-DNA antibodies by bacterial lipopolysaccharides in mice. II. Correlation between anti-DNA induction and polyclonal antibody formation by various polyclonal B lymphocyte activators. J. Immunol. 119:1977;2157-2168.
28. Johansson U., Hansson-Georgiadis H., Hultman P. Murine silver-induced autoimmunity: silver shares induction of antinucleolar antibodies with mercury, but causes less activation of the immune system. Int. Arch. Allergy Immunol. 113:1997;432-443.
29. Johansson U., Hansson-Georgiadis H., Hultman P. The genotype determines the B cell response in mercury-treated mice. Int. Arch. Allergy Appl. Immunol. 116:1998;295-305.
30. Jones M., Harris G. Prolongation of life in female NZB/NZW (f1) hybrid mice by cyclosporin A. Clin. Exp. Immunol. 59:1985;1-9.
31. Kono D., Balomenos D., Pearson D., Park M., Hildebrandt B., Hultman P., Pollard K. Systemic autoimmunity indiced by mercury is dependent on IFN-gamma but not Th1/Th2 imbalance. J. Immunol. 161:1998;234-240.
32. Kubicka-Muranyi M., Behmer O., Uhrberg M., Klonowski H., Bister J., Gleichmann E. Murine systemic autoimmune disease induced by mercuric chloride (HgCl2): Hg-specific helper T-cells react to antigen stored in macrophages. Int. J. Immunopharmacol. 15:1993;151-161.
33. Kuhn R., Rajewski K., Mueller W. Generation and analysis of interleukin-4 deficient mice. Science. 254:1991;707-710.
34. Lillevang S.T., Rosenkvist J., Andersen C.B., Larsen S., Kemp E., Kristensen T. Single and combined effects of the vitamin D analogue KH1060 and cyclosporin A on mercuric-chloride-induced autoimmune disease in the BN rat. Clin. Exp. Immunol. 88:1992;301-306.
35. Maini R.N., Taylor P.C. Anti-cytokine therapy for rheumatoid arthritis. Annl. Rev. Med. 51:2000;207-229.
36. Mirtcheva J., Pfeiffer C., De Bruijn J.A., Jaquesmart F., Gleichmann E. Immunological alterations inducible by mercury compounds. III. H-2A acts as an immune response and H-2E as an immune "suppression" locus for HgCl2-induced antinucleolar antibodies. Eur. J. Immunol. 12:1989;2257-2261.
37. Nielsen J.B., Hultman P. Mercury-induced autoimmunity in mice. Env. Health Perspect. 110:2002;S5877-S5881.
38. Nigai H., Hiyama H., Matsuo A., Ueda Y., Inagaki N., Kawada K. FK-506 and cyclosporin A potentiate the IgE antibody production by contact sensitization with hapten in mice. J. Pharmacol. Exp. Ther. 283:1997;321-327.
39. Ochel M., Vohr H.W., Pfeiffer C., Gleichmann E. Il-4 is required for the IgE and IgG1 increase and IgG1 autoantibody formation in mice treated with mercuric chloride. J. Immunol. 146:1991;3006-3011.
40. Pelletier L., Pasquier R., Rossert J., Vial M.C., Druet P. Autoreactive T cells in mercury-induced autoimmune disease. Ability to induce the autoimmune disease. J. Immunol. 140:1988;750-754.
41. Pollard K., Lee D., Casiano C., Blüthner M., Johnston M., Tan E. The autoimmunity-inducing xenobiotic mercury interacts with the autoantigen fibrillarin and modifies its molecular and antigenic properties. J. Immunol. 158:1997;3521-3528.
42. Pollard K., Pearson D., Blüthner M., Tan E. Proteolytic cleavage of a self-antigen following xenobiotic-induced cell death produces a fragment with novel immunogenic properties. J. Immunol. 165:2000;2263-2270.
43. + T-cells by anti-CD4 monoclonal antibody (GK1.5) in young and aged mice. J. Immunol. 154:1995;6644-6654.
44. Shizuru J.A., Alters S.E., Fathman C.G. Anti-CD4 monoclonal antibodies in therapy: creation of nonclassical tolerance in the adult. Immunol. Rev. 129:1992;105-118.
45. Yamamoto K., Mori A., Nakahama T., Ito T., Okudaira H., Miyamoto T. Experimental treatment of autoimmune MRL-lpr/lpr mice with the immunosuppressive compound FK506. Immunology. 69:1990;222-227.